Targeting EZH2 with specific inhibitors is particularly relevant in ARID1A-mutated cancers since EZH2 is known to influence tumor-infiltrating lymphocytes, thereby contributing to creating an immunosuppressive tumor microenvironment that facilitates immune evasion by tumor cells [47,49,50]. Here, ARID1A is linked to cancer.